Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials Supported by the National Cancer Institute

Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.

To find other cancer trials open to enrollment:

  • Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
  • Use the clinical trials search form to look online for trials listed on NCI's website. The form has a Help link for tips about searching for clinical trials.
  • For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
  • Preventing Graft-versus-Host Disease during Hematologic Cancer Treatment
    (Posted: 05/31/2005, Updated: 04/21/2015) - Researchers are investigating whether an immunosuppressive drug, sirolimus, can work with cyclosporine to prevent graft-versus-host disease (GVHD) more effectively than cyclosporine alone following allogeneic hematopoietic stem cell transplantation.
  • Treating High-grade Lesions to Prevent Anal Cancer in HIV-infected People
    (Posted: 03/11/2015) - This study, called the ANCHOR trial, will investigate whether screening and prevention methods similar to those used to prevent cervical cancer can help prevent anal cancer in HIV-infected men and women.
  • Monoclonal Antibody Therapy for Relapsed or Treatment-Resistant Neuroblastoma
    (Posted: 09/09/2014) - NCI is sponsoring two clinical trials of a monoclonal antibody called ch14.18, in combination with other drugs, to see if the antibody may be helpful for children or young adults (up to age 21) with relapsed or refractory high-risk neuroblastoma.
  • Redefining Adjuvant Therapy for Stage III Resected Colon Cancer
    (Posted: 07/03/2014) - In this trial, patients with resected stage III colon cancer are being randomly assigned to receive a type of chemotherapy called FOLFOX for either 3 months or 6 months and to take either an aspirin-like pill called celecoxib (Celebrex®) or a matching placebo pill for 3 years.
  • Refining Preoperative Therapy for Locally Advanced Rectal Cancer
    (Posted: 04/25/2014) - In the current clinical trial, dubbed PROSPECT, patients with locally advanced, resectable rectal cancer will be randomly assigned to receive either standard neoadjuvant chemoradiation therapy or neoadjuvant FOLFOX chemotherapy, with chemoradiation reserved for those patients who cannot tolerate or do not respond to FOLFOX chemotherapy.
1 2 3 4 5 6 7 8  Next >